THIS WEBSITE IS INTENDED FOR U.S. RESIDENTS ONLY
FOR HEALTHCARE PROFESSIONALS
THIS WEBSITE IS INTENDED FOR U.S. RESIDENTS ONLY | FOR HEALTHCARE PROFESSIONALS

CHOOSE A BOWEL PREP THAT FOLLOWS THE GUIDELINES1,2

Review Guidelines
Actor portrayal.

The US Multi-Society Task Force on Colorectal Cancer* recently raised the standard for bowel prep adequacy from ≥85% to ≥90%. The guidelines have been put into place to ensure that the medicines you take meet medical standards for effectiveness.1,2

So whether it’s a liquid or tablet, you can feel confident either bowel prep will meet or exceed experts’ recommendations.1,2

Choose a Bowel Prep That Exceeds the ≥90% Adequacy Target1-5

99%
of patients achieved prep adequacy
with SUFLAVE®3
97%
of patients achieved prep adequacy
with SUTAB®4,5

Choose a Bowel Prep That’s Easy to Take3-5

87%
of patients found SUFLAVE® tolerable
to very easy to consume3
79%
of patients found SUFLAVE® neutral
to very pleasant3
  • The majority of patients said SUFLAVE®
    tastes like a sports drink    3
91%
of patients in one pivotal trial rated SUTAB®
as tolerable to very easy to consume4†
78%
of patients in one pivotal trial would request
SUTAB® again for a future colonoscopy5†

Your Bowel Prep, Your Choice

Study Design for SUFLAVE®3,6: This phase 3 trial was conducted in multiple sites. Of the 500 subjects who enrolled, 450 were evaluable for efficacy analyses. The primary endpoint was the percentage of subjects with successful cleansing, which was defined as a rating of excellent or good as assigned by the local endoscopist utilizing the US FDA Bowel Prep Scoring Scale. Secondary endpoints included prep adequacy, cecal intubation and adenoma detection rates, procedure duration, and intraprocedural water. Independent central readers also reviewed all colonoscopy videos and provided a global cleansing grade, as well as segmental grades, on insertion and withdrawal using a 4-point scale of excellent, good, fair, and poor. The goal of the study was to establish non-inferiority of SUFLAVE® to SUPREP® Bowel Prep Kit, using a 10% margin. Most common adverse reactions (≥2%) are: nausea, abdominal distension, vomiting, abdominal pain, and headache.
Study Design for SUTAB®5: This phase 3 trial was conducted in 22 US sites. Of the 620 subjects who enrolled, 548 patients were evaluable for efficacy analyses. The primary endpoint was the percentage of subjects with successful cleansing, which was based on the US FDA Bowel Prep Scoring Scale, the goal of which was to determine non-inferiority against MoviPrep®. Safety follow-up visits were required 24-48 hours after colonoscopy and on days 7 and 30 if adverse events or lab abnormalities were indicated. The primary endpoint of non-inferiority was met.
*
US Multi-Society Task Force on Colorectal Cancer is comprised of the American College of Gastroenterology®, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy®. Their goal is to ensure that patients receive the correct procedure and diagnosis, that therapy is properly performed, and that all this is accomplished with minimum risk. Visit https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104386/ to learn more.
†
Patients completed a preference questionnaire following completion of study drug to capture their perceptions of the preparation experience. This questionnaire has not undergone formal validation.
MoviPrep® is a registered trademark of Velinor AG.
IMPORTANT SAFETY INFORMATION

SUFLAVE® (polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution)

Indications and Usage

SUFLAVE is indicated for the cleansing of the colon as a preparation for colonoscopy in adults.

ADDITIONAL IMPORTANT SAFETY INFORMATION

What is the most important information I should know about SUFLAVE?

SUFLAVE and other bowel preparations can cause serious side effects, including:
Serious loss of body fluid (dehydration) and changes in body salts (electrolytes) in your blood.

These changes can cause:

  • abnormal heartbeats that can cause death.
  • seizures. This can happen even if you have never had a seizure.
  • kidney problems.

Do not take SUFLAVE if your healthcare provider has told you that you have:

  • a blockage in your bowel (obstruction) or a problem with food moving too slowly through your intestines (ileus).
  • an opening in the wall of your stomach or intestine (bowel perforation).
  • a very dilated intestine (toxic colitis or toxic megacolon).
  • problems with food and fluid emptying from your stomach (gastric retention).
  • allergies to any ingredient in SUFLAVE.

What are the possible side effects of SUFLAVE?

SUFLAVE can cause serious side effects, including:
  • Changes in certain blood tests. Your healthcare provider may do blood tests after you take SUFLAVE to check your blood for changes. Tell your healthcare provider if you have any symptoms of too much fluid loss, including:
  1. vomiting
  2. dizziness
  3. urinate less than usual
  1. nausea
  2. stomach (abdominal) cramping
  3. trouble drinking clear liquid
  1. bloating
  2. headache
  1. vomiting
  2. dizziness
  3. urinate less than usual
  4. nausea
  5. stomach (abdominal) cramping
  6. trouble drinking clear liquid
  7. bloating
  8. headache
  • Heart problems. SUFLAVE may cause abnormal heartbeats.
  • Seizures.
  • Ulcers of the bowel or bowel problems (ischemic colitis). Tell your healthcare provider right away if you have severe stomach-area (abdominal) pain or rectal bleeding.
  • Serious allergic reactions. Get medical help right away if you have any signs and symptoms of a serious allergic reaction while taking SUFLAVE, including:
  1. difficulty breathing
  2. swelling of the face, lips, tongue and throat
  3. raised red patches on your skin (hives)
  1. skin rash
  2. itching
  1. difficulty breathing
  2. swelling of the face, lips, tongue and throat
  3. raised red patches on your skin (hives)
  4. skin rash
  5. itching

Before taking SUFLAVE, tell your healthcare provider about all of your medical conditions, including if you:

  • have problems with serious loss of body fluid (dehydration) and changes in blood salts (electrolytes).
  • have heart problems.
  • have stomach or bowel problems including ulcerative colitis.
  • have problems with swallowing or gastric reflux, or if you inhale food or fluid into your lungs when eating or drinking (aspirate).
  • have a history of seizures.
  • are withdrawing from drinking alcohol or from taking benzodiazepines.
  • have a low blood salt (sodium) level.
  • have kidney problems.
  • are pregnant. It is not known if SUFLAVE will harm your unborn baby. Talk to your healthcare provider if you are pregnant.
  • are breastfeeding or plan to breastfeed. It is not known if SUFLAVE passes into your breast milk. You and your healthcare provider should decide if you will take SUFLAVE while breastfeeding.

Tell your healthcare provider about all the medicines you take, including

  • Prescription and over-the-counter medicines, vitamins, and herbal supplements.
  • SUFLAVE may affect how other medicines work. Medicines taken by mouth may not be absorbed properly when taken within 1 hour before the start of each dose of SUFLAVE.
  • Especially tell your healthcare provider if you take: medicines to treat a blood salt (electrolyte) imbalance, medicines for blood pressure, heart problems, kidney problems, or seizures, water pills (diuretics), non-steroidal anti-inflammatory drugs (NSAIDs), medicines for depression or other mental health problems, and laxatives. Do not take other laxatives while taking SUFLAVE
  • starch-based thickeners. For patients who have trouble swallowing, do not mix SUFLAVE with starch-based thickeners.
    The following medicines should be taken at least 2 hours before starting each dose of SUFLAVE and not less than 6 hours after taking each dose of SUFLAVE:
  1. tetracycline
  2. fluoroquinolone antibiotics
  1. iron
  2. digoxin
  1. chlorpromazine
  2. penicillamine
  1. tetracycline
  2. fluoroquinolone antibiotics
  3. iron
  4. digoxin
  5. chlorpromazine
  6. penicillamine

The most common side effects of SUFLAVE include:

  • nausea
  • stomach-area swelling (abdominal distension)
  • Vomiting
  • Upper stomach (abdominal) pain
  • nausea
  • stomach-area swelling (abdominal distension)
  • Vomiting
  • Upper stomach (abdominal) pain

These are not all the possible side effects of SUFLAVE.

The Important Safety Information does not include all the information needed to use SUFLAVE safely and effectively. Please see accompanying full Prescribing Information for SUFLAVE.

To Report SUSPECTED ADVERSE REACTIONS, contact Azurity Pharmaceuticals, Inc. at 1-800-461-7449, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.

SUFLAVE® is a registered trademark of Azurity Pharmaceuticals, Inc.

PP-SUF-7061-US-EN-v1 03/26

IMPORTANT SAFETY INFORMATION

SUTAB® (sodium sulfate, magnesium sulfate, and potassium chloride) tablets, for oral use

Indications and Usage

SUTAB is indicated for the cleansing of the colon as a preparation for colonoscopy in adults.

ADDITIONAL IMPORTANT SAFETY INFORMATION

What is the most important information I should know about SUTAB?

SUTAB and other bowel preparations can cause serious side effects, including:
Serious loss of body fluid (dehydration) and changes in body salts (electrolytes) in your blood.

These changes can cause:

  • Abnormal heartbeats that can cause death.
  • Seizures. This can happen even if you have never had a seizure.
  • Kidney problems.

Do not take SUTAB if your healthcare provider has told you that you have:

  • a blockage in your bowel (obstruction) or a problem with food moving too slowly through your intestines (ileus).
  • an opening in the wall of your stomach or intestine (bowel perforation).
  • a very dilated intestine (toxic colitis or toxic megacolon).
  • problems with food and fluid emptying from your stomach (gastric retention).
  • allergies to any ingredient in SUTAB.

What are the possible side effects of SUTAB?

SUTAB can cause serious side effects, including:
  • Changes in certain blood tests. Your healthcare provider may do blood tests after you take SUTAB to check your blood for changes. Tell your healthcare provider if you have any symptoms of too much fluid loss, including:
  1. vomiting
  2. dizziness
  3. urinate less than usual
  1. nausea
  2. stomach (abdominal) cramping
  3. trouble drinking clear liquid
  1. bloating
  2. headache
  1. vomiting
  2. dizziness
  3. urinate less than usual
  4. nausea
  5. stomach (abdominal) cramping
  6. trouble drinking clear liquid
  7. bloating
  8. headache
  • Heart problems. SUTAB may cause abnormal heartbeats.
  • Seizures.
  • Ulcers of the bowel or bowel problems (ischemic colitis). Tell your healthcare provider right away if you have severe stomach-area (abdominal) pain or rectal bleeding.
  • Serious allergic reactions. Get medical help right away if you have any signs and symptoms of a serious allergic reaction while taking SUTAB, including:
  1. swelling of your hands, face lips, mouth or tongue
  2. breathing problems
  3. raised red patches on your skin
  1. rash
  2. severe itching
  1. swelling of your hands, face lips, mouth or tongue
  2. breathing problems
  3. raised red patches on your skin
  4. rash
  5. severe itching
  • Take SUTAB exactly as your healthcare provider tells you. Each SUTAB bottle contains a drying agent (desiccant) to keep the tablets dry. Do not swallow the desiccant. Remove and throw away the desiccant from both bottles the evening before your colonoscopy. Swallowing the desiccant by mistake has been reported and may cause choking or stomach and bowel problems.

Before taking SUTAB, tell your healthcare provider about all of your medical conditions, including if you:

  • have heart problems.
  • have stomach or bowel problems including ulcerative colitis.
  • have problems with swallowing or gastric reflux.
  • have a history of seizures.
  • are withdrawing from drinking alcohol or from taking benzodiazepines.
  • have a low blood salt (sodium) level.
  • have kidney problems.
  • are pregnant. It is not known if SUTAB will harm your unborn baby. Talk to your healthcare provider if you are pregnant.
  • are breastfeeding or plan to breastfeed. It is not known if SUTAB passes into your breast milk. You and your healthcare provider should decide if you will take SUTAB while breastfeeding.

Tell your healthcare provider about all the medicines you take, including

  • Prescription and over-the-counter medicines, vitamins, and herbal supplements.
  • SUTAB may affect how other medicines work. Medicines taken by mouth may not be absorbed properly when taken within 1 hour before the start of each dose of SUTAB.
  • Especially tell your healthcare provider if you take: medicines for blood pressure or heart problems, kidney problems, or seizures, water pills (diuretics), non-steroidal anti-inflammatory drugs (NSAIDs), medicines for depression or other mental health problems, and laxatives. Do not take other laxatives while taking SUTAB.
  • The following medicines should be taken at least 2 hours before starting each dose of SUTAB and not less than 6 hours after taking each dose of SUTAB:
  1. tetracycline
  2. fluoroquinolone antibiotics
  1. iron
  2. digoxin
  1. chlorpromazine
  2. penicillamine
  1. tetracycline
  2. fluoroquinolone antibiotics
  3. iron
  4. digoxin
  5. chlorpromazine
  6. penicillamine

The most common side effects of SUTAB include:

  • nausea
  • stomach-area swelling (abdominal distension)
  • Vomiting
  • Upper stomach (abdominal) pain
  • nausea
  • stomach-area swelling (abdominal distension)
  • Vomiting
  • Upper stomach (abdominal) pain

These are not all the possible side effects of SUTAB.

The Important Safety Information does not include all the information needed to use SUTAB safely and effectively. Please see accompanying full Prescribing Information for SUTAB.

To Report SUSPECTED ADVERSE REACTIONS, contact Azurity Pharmaceuticals, Inc. at 1-800-461-7449, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.

SUTAB® is a registered trademark of Azurity Pharmaceuticals, Inc.

PP-STB-7062-US-EN-v1 03/26

References: 1. Rex DK, Anderson JC, Butterfly LF, et al. Quality indicators for colonoscopy. Gastrointest Endosc. 2024;100(3):352-381. doi:10.1016/j.gie.2024.04.2905 2. Jacobson BC, Anderson JC, Burke CA, et al. Optimizing bowel preparation quality for colonoscopy: consensus recommendations by the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2025;120(4):738-764. doi:10.14309/ajg.0000000000003287 3. Bhandari R, Goldstein M, Mishkin DS, et al. Comparison of a novel, flavor-optimized, polyethylene glycol and sulfate bowel preparation with oral sulfate solution in adults undergoing colonoscopy. J Clin Gastroenterol. 2023;57(9):920-927. doi:10.1097/MCG.0000000000001894 4. Di Palma JA, Bhandari R, Cleveland M, et al. A safety and efficacy comparison of a new sulfate-based tablet bowel preparation versus a PEG and ascorbate comparator in adult subjects undergoing colonoscopy. Am J Gastroenterol. 2021;116(2):319-328. doi:10.14309/ajg.0000000000001020 5. SUFLAVE® [package insert]. Woburn, MA: Azurity Pharmaceuticals, Inc. 6. SUTAB® [package insert]. Woburn, MA: Azurity Pharmaceuticals, Inc. 7. National Cancer Institute. Cancer stat facts: colorectal cancer. Accessed June 8, 2026. https://seer.cancer.gov/statfacts/html/colorect.html. 8. American College of Gastroenterology. Colorectal cancer: you can prevent it. Accessed June 8, 2026. https://webfiles.gi.org/links/committees/Public%20Relations/crc-awareness/crc_rackcard_2026.pdf. 9. American College of Gastroenterology. You can prevent colorectal cancer: don't let COVID-19 stop you. Accessed June 8, 2026. https://webfiles.gi.org/links/committees/Public%20Relations/21CRC-Rack-Card-Prevent-CRC-Dont-Let-COVID-Stop-You.pdf. 10. American College of Gastroenterology. 45 is the new 50! Accessed June 8, 2026. https://webfiles.gi.org/links/committees/Public%20Relations/crc-awareness/crc_45new50_trifold_2026.pdf.

Please see SUFLAVE.com and SUTAB.com for Full Prescribing Information and Medication Guides.
© 2026 Azurity Pharmaceuticals, Inc. All rights reserved. PP-STB-SUF-7272-US-EN-v2 July 2026
Please see Full Prescribing Information and Medication Guides for SUFLAVE and SUTAB.